Eli Lilly & Co snagged a win (or at least avoided a loss) this week, announcing that its projected blockbuster GLP-1 agonist diabetes medication dulaglutide was comparable to current lead treatment Victoza (liraglutide) by Novo Nordisk .
Help employers find you! Check out all the jobs and post your resume.
